Figure 3.

First-pass isolation rate (A), recurrence-free rates at 12 months (B), and re-ablation-free rates at 12 months (C) in MIYABI, US SURPOINT COA⁷ and Europe VISTAX⁶ studies. Definition of first-pass isolation rate for each study: MIYABI, PVI after a first encirclement that remained isolated until the end of the procedure; US SURPOINT COA, PVI toward the end of the procedure confirmed by an entrance block; Europe VISTAX, first-pass isolation proof to a 30-min wait period and adenosine challenge. Rates were determined by standard-of-care monitoring. AF, atrial fibrillation; PVI, pulmonary vein isolation.